European GeneICE Patent Granted and CRT Trials ...
For immediate release: 07.00hrs 8 August 2007
VALIRX PLC
("ValiRx")
European GeneICE Patent Granted and CRT Trials Update
ValiRx (AIM: VAL), the cancer therapeutics company, today announces that its
proprietary gene-silencing technology, GeneICE, has received patent approval by
the European Patent Office covering 23 European states*. This follows the
granting of a US patent in April 2007.
ValiRx holds the rights to GeneICE through its subsidiary, Cronos Therapeutics
Ltd ("Cronos"), which has an exclusive worldwide license agreement with
Imperial College Innovations.
GeneICE compounds have the potential to freeze the development and growth of
cancerous cells and also have potential major applications in inflammatory
disease and inherited genetic conditions. Cronos' partner, Cancer Research UK,
a prestigious research institute in Europe, is currently undertaking
pre-clinical trials on GeneICE through Cancer Research Technology Limited
("CRT").
Dr Satu Vainikka, CEO of ValiRx, commented:
"We are delighted to have received this European patent which makes the
technology securely protected in the world's major life science markets: the US
and Europe. We anticipate being able to update the market regarding the initial
results from CRT's pre-clinical trials on GeneICE in September."
---ENDS---
Notes to Editors
* European countries include Austria, Belgium, Bulgaria, Switzerland, Cyprus,
Czech Republic, Germany, Denmark, Estonia, Spain, Finland, France, the United
Kingdom, Greece, Ireland, Italy, Luxembourg, Monaco, the Netherlands, Portugal,
Sweden, Slovakia and Turkey.
Information on ValiRx
ValiRx is a biopharmaceutical development company that is building a portfolio
of complementary cancer-related therapeutic and diagnostic technologies. It
currently holds stakes in Cronos and Morphogenesis Inc.:
* Cronos holds licenses to two innovative and potentially market changing
technologies, GeneICE and HyperGenomics, as well as having an extensive
portfolio of pending and granted patents in the areas of gene regulation
and epigenetic diagnostic technologies;
* Morphogenesis Inc. is developing a portfolio of cell therapy products for
the treatment of chronic disorders. Its most advanced product, being
ImmuneFxâ„¢ for which it recently received a patent from the US patent
office.
ValiRx is headquartered in London, England.
For further information, please visit www.valirx.com
Contact Details:
ValiRx Plc WH Ireland GTH Communications
Satu Vainikka David Youngman Toby Hall / Jade
Mamarbachi
+44 (0) 203 008 4416 +44 (0) 161 832 +44 (0) 20 7153 8035
2174
AI Summary Disclaimer BETA
The content you are viewing has been generated or assisted by artificial
intelligence (AI). While efforts are made to ensure accuracy and clarity, AI-generated text may
contain inaccuracies, outdated information, or subjective interpretations. This content is intended
for general informational purposes only and should not be considered professional advice or factual
confirmation.
We encourage you to independently verify any information provided,
especially if it will be relied upon for making decisions or taking action. Any reliance you place
on this material is strictly at your own risk. The AI system that produced this content cannot
assess the specifics of individual circumstances, and results may vary based on context and
individual needs.
*A Private Investor is a recipient of the information who meets all of the conditions set out below, the recipient:
Obtains access to the information in a personal capacity;
Is not required to be regulated or supervised by a body concerned with the regulation or supervision of investment or financial services;
Is not currently registered or qualified as a professional securities trader or investment adviser with any national or state exchange, regulatory authority, professional association or recognised professional body;
Does not currently act in any capacity as an investment adviser, whether or not they have at some time been qualified to do so;
Uses the information solely in relation to the management of their personal funds and not as a trader to the public or for the investment of corporate funds;
Does not distribute, republish or otherwise provide any information or derived works to any third party in any manner or use or process information or derived works for any commercial purposes.
Please note, this site uses cookies. Some of the cookies are essential for parts of the site to operate and have already been set. You may delete and block all cookies from this site, but if you do, parts of the site may not work. To find out more about the cookies used on Investegate and how you can manage them, see our Privacy and Cookie Policy
To continue using Investegate, please confirm that you are a private investor as well as agreeing to our Privacy and Cookie Policy & Terms.
Create an Account
Create your FREE account to receive personalised announcements, watchlists, market updates, investment insights and new features.
Personalise your experience
Tell us a little about yourself to receive personalised content, announcements and relevant investment opportunities.